TR-1: Standard form for notification of major holdings
1. Issuer Details
ISIN
GB0009633180
Issuer Name
DECHRA PHARMACEUTICALS PLC
UK or Non-UK Issuer
UK
2. Reason for Notification
An acquisition or disposal of voting rights; Other
Comments
UBS trading book holdings in Dechra Pharmaceuticals PLC fell below 5% and are therefore exempt from reporting
3. Details of person subject to the notification obligation
Name
UBS Group AG Investment Bank
City of registered office (if applicable)
London
Country of registered office (if applicable)
United Kingdom
4. Details of the shareholder
Full name of shareholder(s) if different from the person(s) subject to the notification obligation, above
City of registered office (if applicable)
Country of registered office (if applicable)
5. Date on which the threshold was crossed or reached
30-Nov-2023
6. Date on which Issuer notified
04-Dec-2023
7. Total positions of person(s) subject to the notification obligation
% of voting rights attached to shares (total of 8.A) |
% of voting rights through financial instruments (total of 8.B 1 + 8.B 2) |
Total of both in % (8.A + 8.B) |
Total number of voting rights held in issuer |
|
Resulting situation on the date on which threshold was crossed or reached |
0.000000 |
0.000000 |
0.000000 |
0 |
Position of previous notification (if applicable) |
3.388367 |
1.869824 |
5.258191 |
|
8. Notified details of the resulting situation on the date on which the threshold was crossed or reached
8A. Voting rights attached to shares
Class/Type of shares ISIN code(if possible) |
Number of direct voting rights (DTR5.1) |
Number of indirect voting rights (DTR5.2.1) |
% of direct voting rights (DTR5.1) |
% of indirect voting rights (DTR5.2.1) |
GB0009633180 |
|
0 |
|
0.000000 |
Sub Total 8.A |
0 |
0.000000% |
8B1. Financial Instruments according to (DTR5.3.1R.(1) (a))
Type of financial instrument |
Expiration date |
Exercise/conversion period |
Number of voting rights that may be acquired if the instrument is exercised/converted |
% of voting rights |
|
|
|
|
|
Sub Total 8.B1 |
|
|
|
8B2. Financial Instruments with similar economic effect according to (DTR5.3.1R.(1) (b))
Type of financial instrument |
Expiration date |
Exercise/conversion period |
Physical or cash settlement |
Number of voting rights |
% of voting rights |
|
|
|
|
|
|
Sub Total 8.B2 |
|
|
|
9. Information in relation to the person subject to the notification obligation
2. Full chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held starting with the ultimate controlling natural person or legal entities (please add additional rows as necessary)
Ultimate controlling person |
Name of controlled undertaking |
% of voting rights if it equals or is higher than the notifiable threshold |
% of voting rights through financial instruments if it equals or is higher than the notifiable threshold |
Total of both if it equals or is higher than the notifiable threshold |
UBS Group AG (Chain 1) |
|
|
|
|
UBS Group AG (Chain 1) |
UBS AG |
|
|
|
UBS Group AG (Chain 1) |
UBS AG London Branch |
|
|
|
UBS Group AG (Chain 2) |
|
|
|
|
UBS Group AG (Chain 2) |
UBS AG |
|
|
|
UBS Group AG (Chain 2) |
UBS Europe SE |
|
|
|
10. In case of proxy voting
Name of the proxy holder
The number and % of voting rights held
The date until which the voting rights will be held
11. Additional Information
UBS trading book holdings in Dechra Pharmaceuticals PLC fell below 5% and are therefore exempt from reporting.
12. Date of Completion
04-Dec-2023
13. Place Of Completion
Zurich, Switzerland